Effect of ATorvastatin On Chronic subdural Hematoma (ATOCH): a study protocol for a randomized controlled trial by Rongcai Jiang et al.
STUDY PROTOCOL Open Access
Effect of ATorvastatin On Chronic subdural
Hematoma (ATOCH): a study protocol for a
randomized controlled trial
Rongcai Jiang1,2,3,4,5†, Dong Wang1,2,3,4,5†, Wai Sang Poon6, Yi Cheng Lu7, Xin Gang Li8, Shi Guang Zhao9,
Ren Zhi Wang10, Chao You11, Xian Rui Yuan12, Jian Min Zhang13, Hua Feng14, Zhou Fei15, Xin Guang Yu16,
Yuan Li Zhao17, Jin Hu18, De Zhi Kang19, Ru Tong Yu20, Guo Dong Gao21, Xi De Zhu22, Tao Sun23, Jie He Hao24,
Xian Zhi Liu25, Ning Su26, Shu Yuan Yue1,2,3,4,5 and Jian Ning Zhang1,2,3,4,5*
Abstract
Background: Chronic subdural hematoma (CSDH) is a common disease that is more prevalent in older people.
Surgical intervention is a safe treatment of choice. However, the recurrence rate is relatively high and the outcome is
not always satisfactory among surgically treated patients. It is believed that aberrant angiogenesis and intracapsular
inflammation contribute to the development of CSDH. Atorvastatin is reported to promote angiogenesis and suppress
inflammation. We have recently shown that atorvastatin is effective to non-surgically reduce and eliminate CSDH with
minimal side effects. Here, we report a clinical research trial protocol that is designed to evaluate the therapeutic
effects of atorvastatin on CSDH.
Methods/Design: We have designed a multi-center, randomized, placebo-controlled, double blind clinical trial
for evaluating the efficacy of oral atorvastatin in reducing CSDH. We have so far recruited 96 patients with
CT-confirmed or MRI-confirmed CSDHs from 16 medical centers in China. These patients were originally
recruited for the Oriental Neurosurgical Evidence-based Study Team (ONET) study. After informed consent is
provided, patients are randomized to receive either atorvastatin (oral 20 mg/night for 8 weeks) or placebo
(dextrin for 8 weeks); and followed for 16 weeks after the treatment. The primary outcome is the change in
hematoma volume at the end of 8-week treatment. Secondary outcomes include: changes in 1) the
hematoma volume at the 4th, 12th, and 24th weeks; 2) Markwalder’s Grading Scale and Glasgow Coma Scale
(MGS-GCS); 3) Glasgow Outcome Score (GOS) and 4) Activities of Daily Life – the Barthel Index scale (ADL-BI).
Safety will be assessed during the study by monitoring adverse events, laboratory tests, electrocardiography
(ECG), measurements of vital signs (temperature, pulse, and blood pressure) and body weight.
Discussion: Results of this trial will provide critical information regarding whether atorvastatin is an effective
and safe alternative to surgical treatment of CSDH.
Trial registration: ClinicalTrials.gov Identifier – NCT02024373
The date of trial registration: 7 August 2013
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Background
Chronic subdural hematoma (CSDH) is a common type
of encephalic hematoma with an incidence of 5/10,000
in the general population and 58/10,000 in people who
are 70 years or older [1]. Head trauma is the most com-
mon risk factor for CSDH [2], along with age. CSDH oc-
curs in up to 26.5 % of patients who are 65 years or
older. Older patients also have a significantly higher re-
currence rate as compared to the general population [3].
Incidences of CSDH and recurrent CSDH are expected
to raise worldwide with an aging population. In addition,
the increasing use of anticoagulant/antiplatelet therapies
is also a common risk factor for CSDH in patients with-
out a history of trauma [4] and poses a challenge for the
surgical treatment of CSDH. Unlike subacute subdural
hematoma (SSDH), spontaneous reabsorption is rare in
CSDH and surgery has traditionally been the treatment
of choice [5]. However, the rate of recurrent CSDH is
high (approximately 25 %) in surgically treated patients
[6], leading to a mortality of 11.1–13.5 % [7]. The surgi-
cal outcome is particularly poor for patients of 90 years
or older [8].
Because of unsatisfactory outcomes of surgery, sev-
eral adjuvant or conservative therapies have been clin-
ically tested, including corticosteroids, as
complementary therapies [1]. Dexamethasone is re-
ported to effectively reduce the volume of CSDH after
surgery [9–12]. It is also reported that perindopril
(angiotensin converting enzyme inhibitor, ACEI) re-
duces the recrudescence of CSDH after surgery [13].
We have recently reported the effect of atorvastatin
on reducing CSDH in 23 patients [14].
The pathogenesis of CSDH and mechanisms of above
adjuvant therapies remain poorly understood. It has been
reported that a CSDH hematoma contains a large number
of erythrocytes from continuous blood leakage due to
primitively formed blood vessels in the hematoma wall.
Vascular endothelial growth factor (VEGF) is detected at a
significantly high level in hematoma and in the serum of
CSDH patients. [15]. VEGF promotes angiogenesis, but, at
a persistent high level, also inhibits the maturation of new
vessels [16]. We have previously demonstrated the pres-
ence of a pseudo envelope around a subdural hematoma
that contains immature and abnormal vessels [17]. In
addition, a hematoma is also enriched in proinflammatory
cytokines [18–20]. We and other have shown that statins
(hydroxy-methylglutaryl-CoA reductase inhibitors)
mobilize circulating endothelial progenitor cells (EPCs) to
enhance angiogenesis [21–25]. Atorvastatin also inhibits
VEGF and reduces the inflammatory reaction [26, 27] as
well as up-regulating Notch1/Jagged1 signal, which is crit-
ical for VEGF-induced vessel formation and maturation.
These reports led us to hypothesize that atorvastatin mod-
ulates VEGF expression and the level of inflammation in
hematoma, resulting in the shrinkage of CSDH. This
protocol was designed to test this hypothesis.
Methods/Design
Study objective
The primary objective of this trial is to evaluate the effi-
cacy of atorvastatin in reducing or eliminating CSDHs
after 2 months without surgery.
The secondary objectives are to evaluate changes in
hematoma volume (non-enhanced computerized tomog-
raphy (CT) scan) at the 4th week during the treatment;
and at the 12th and 24th weeks during the follow-up
period; and to measure the effect of atorvastatin on im-
proving neurological function in patients with CSDH as
assayed by the MGS-GCS, GOS, and ADL-BI at 4 weeks,
8 weeks and 6 months after atorvastatin therapy is
initiated.
Trial design
The trial is designed as a multi-center, phase II, pro-
spective, double blind, randomized, placebo-controlled
study. Eligible patients are randomized in a 1:1 alloca-
tion ratio to one of the two treatment arms: 20 mg
daily of atorvastatin (treatment) and placebo drug
(control). The treatment will continue for 8 weeks
followed by 16 weeks of follow-up.
Patients will be recruited from 16 neurosurgery cen-
ters in China that are participants in the Oriental Neuro-
surgical Evidence-based Study Team (ONET) (Table 1,
additional ethics documentations in Additional file 1).
ONET is chaired by the Department of Neurosurgery,
Tianjin Medical University General Hospital. Before the
enrollment, patients or their family guardians will be
fully informed about the trial, its potential outcomes and
adverse events; and provide informed consent. The in-
formed consent forms are in Chinese and English. The
study will be conducted according to the Declaration of
Helsinki. The ethics boards of Tianjin Medical Univer-
sity General Hospital and other participating hospitals
have approved this study.
Inclusion criteria
The inclusion criteria are CSDH patients who: (1)
are ≥ 18 and < 90 years old of either gender; (2) have
evidence of supratentorial, unilateral or bilateral
CSDH by CT scan (magnetic resonance imaging
(MRI) scan is warranted if diagnosis is difficult); (3)
have MGS-GCS < Grade 3 (Additional file 2); (4) have
no cerebral herniation and immediate needs for sur-
gery (as determined by 2 attending physicians); (5)
have had no previous surgery on CSDH; and (6) fully
understand the nature of this trial and provide in-
formed consent.
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Exclusion criteria
The exclusion criteria are: (1) allergic to statins or
their ingredients; (2) cerebral herniation; (3) subdural
hematoma caused by tumors, hematologic diseases or
other known severe comorbidities such as multiple
organ failure, uncontrolled diabetes mellitus and heart
failure; (4) abnormal liver function or liver diseases
including uncontrolled hepatitis; (5) other diseases
that may interfere with the study as determined by
2 attending neurosurgeons; (6) patients on oral
statin medication for more than 1 week before
randomization or who are expected to take statins in
the next 6 months; (7) patients on oral steroids for
more than 1 week before randomization or who are
expected to take such medications in the next
6 months; (8) a participant in clinical trials in the
past 4 weeks; (9) pregnancy or breastfeeding; (10) fail-
ure to complete the trial by poor compliance; (11)
other conditions that render a patient unsuitable for
the trial as determined by the study investigators.
Medication and placebo
The 10-mg tablet of atorvastatin is provided by Pfizer,
Inc. and taken orally at 20 mg daily before bed. The
placebo drug matching oral atorvastatin is made of
dextrin with the same weight and appearance and
made by Shandong ARURA Pharmaceutical Research
& Development. Co., Ltd. with the certification of
good manufacturing practice (GMP) for pharmaceut-
ical products issued by the China Food and Drug Ad-
ministration (CFDA).
Atorvastatin and placebo are packed identically and
labeled with packaging number, verification code, dos-
age, specifications, storage, batch number, the dur-
ation of usage, and manufacturer. The package will be
labeled: “for clinical study use only.”
Randomization
Eligible subjects are assigned randomly to either statin
or placebo group through the Central Randomization
System. The Data Acquisition System for Electronic
Data Capture (DAS for EDC) 5.0 (Beijing Stemexcel
Technology Co., Ltd., Beijing, China) will be used to
produce random numbers. An EDC system is a com-
puterized system designed for the collection of clin-
ical data in electronic format for use mainly in
human clinical trials. The ratio of experimental and
control group is calculated, by a biostatistician inde-
pendent of the study data management and statistical
analysis, to be 1:1.
After initial screening, an investigator will log onto
the Central Randomization System to enter demo-
graphic information of an enrolled patient to produce
a random number application. A designated individual
Table 1 Medical centers in China participating in the study
Medical centers Ethics committee
1. Tianjin Medical University, General Hospital Medical Ethics Committee of Tianjin Medical University General Hospital
2. Peking Union Medical College Hospital Ethics Committee of Peking Union Medical College Hospital Affiliated to Chinese
Academy of Medical Sciences
3. Prince of Wales Hospital, Hong Kong Pharmacy and Poisons Board of Hong Kong
4. Qilu Hospital of Shandong University Medical Ethics Committee of Qilu Hospital Affiliated to Shandong University
5. The First Affiliated Hospital of Zhengzhou University Clinical Trial Ethics Committee of First Affiliated Hospital of Zhengzhou University
6. The Second Affiliated Hospital of Zhejiang University School of
Medicine
Human Research Ethics Committee of the Second Affiliated Hospital of Zhejiang
University School of Medicine
7. First Affiliated Hospital of Fujian Medical University Medical Ethics Committee of First Affiliated Hospital of Fujian Medical University
8. First Affiliated Hospital of Shanxi Medical University Science/Medical Experimental Ethics Committee of First Affiliated Hospital of
Shanxi Medical University
9. General Hospital of Ningxia Medical University Scientific Experiment Ethics Committee of Ningxia Medical University General
hospital
10. Linyi People’s Hospital Medical Ethics Committee of Linyi People’s Hospital
11. Southwest Hospital The First Affiliated Hospital of the Third
Military Medical University
Ethics Committee of the First Affiliated Hospital of Third Military Medical
University, PLA
12. Tangdu Hospital, The Second Affiliated Hospital of the Fourth
Military Medical University
IEC of Institution for National Drug Clinical Trials, Tangdu Hospital, Fourth Military
Medical University
13. The Affiliated Hospital of Xuzhou Medical College Medical Ethics Committee of Affiliated Hospital of Xuzhou Medical College
14. The First Affiliated Hospital of Harbin Medical University Medical Ethics Committee of First Hospital Affiliated to Harbin Medical University
15. Xijing Hospital, The First Affiliated Hospital of the Fourth
Military Medical University
IEC of First Affiliated Hospital of Fourth Military Medical University
16. Inner Mongolia People's Hospital Ethics Committee of Inner Mongolia People's Hospital
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will then apply for a drug package number and dis-
pense the drug when the package number is consist-
ent with the one recorded in the database.
Treatment and intervention
Atorvastatin: oral intake of a 20 mg Atorvastatin tablet
daily for 8 weeks.
Placebo: oral intake of a placebo tablet daily for
8 weeks.
At the end of the 8-week treatment, the volume of
hematoma will be evaluated by CT scan for the following
outcomes:
1. A hematoma disappears or is significantly reduced
from the size measured before the treatment.
Regardless of whether a smaller hematoma
remains, the patient will enter into the follow-up
period and should not be continuously treated
with atorvastatin.
2. A hematoma does not change significantly or
increases by CT scan at the end of 8 weeks of
treatment (this can occur in patients who receive
placebo). At the end of atorvastatin treatment,
attending surgeons can decide if these patients
need to receive surgery. The detailed medication
and treatment during the process will be
continuously recorded for 24 weeks.
3. For any patients whose hematoma increases as
determined by CT scan and/or neurological
deficits progress during the follow-up period, he
or she may undergo surgery. The detailed medica-
tion and treatments during the process will be re-
corded for 24 weeks.
Timeline schedule
Protocol-mandated assessments will be performed ac-
cording to the schedule (Table 2). The study flow chart
illustrates key steps of the trial (Fig. 1).
Concomitant care
All patients in the study will receive routine laboratory
assessments, including complete blood count (CBC), co-
agulation (international normalized ratio, INR), liver and
renal function, blood lipids and urinalysis. Head CT im-
ages will be recorded in Digital Imaging and Communi-
cation in Medicine (DICOM) format and evaluated
centrally in a triple-blinded manner. Blood samples will
be analyzed in a local laboratory and saved in a Case Re-
port Form (CRF) format. The 4 regular follow-up visits
are scheduled at the 4th, 8th, 12th and 24th weeks after
the initiation of atorvastatin treatment.
The ACEIs (such as perindopril, captopril, enalapril)
are reported to eliminate CSDH [9, 28] and are thus
their use is not allowed during the course of atorvastatin
treatment. Anticoagulants (warfarin or new oral antico-
agulants), antiplatelet drugs (aspirin, clopidogrel) or
Xuesaitong (traditional Chinese medicine for activating
blood circulation) can potentially interfere with
hematoma absorption and are not recommended during
the treatment. However, these patients will not be exclu-
sively excluded from the trial participation. The follow-
ing drugs may potentially interact with statins and/or
cause adverse events [29] and will not be recommended
during the treatment: red yeast rice, erythromycin,
fibrates, cyclosporin, macrolide antibacterials, azole anti-
fungals, tacrolimus, gemfibrozil, troglitazone, and itraco-
nazole. The use of any medications will be recorded if
they are used concomitantly during atorvastatin treat-
ment in CRF, including name, dosing and duration of
these medications.
Most participants are treated as outpatients receiving
conventional and standard cares such as rest and pain
relief. Family members are responsible for monitoring
patients for progress in neurological symptoms such as
worsening headache. If a patient is reported to have
worsening symptoms, he or she will be further evaluated
by two attending physicians for neurological deficits.
These patients may be admitted during the trial for
treatment of progressing neurological deficits and dis-
charged when their symptoms are relieved significantly.
Whether these patients remain on the trial as inpatients
will be determined on a case-by-case basis by two par-
ticipating investigators/surgeons.
Outcomes
The primary outcome is the change of hematoma vol-
ume 8 weeks after atorvastatin treatment on non-
enhanced CT scan.
Secondary outcomes are changes of hematoma volume
at the 4th, 12th, and 24th weeks; MGS- GCS, GOS and
ADL-BI scores; and improvements in neurological symp-
toms and signs and laboratory tests.
Sample size
We have previous shown, in a pilot study of a small pa-
tient cohort, that a significant reduction in hematoma
volume was found in 95.7 % of CSDH patients treated
with atorvastatin. This result provides a base for the
power calculation of this trial where we assume that
80 % of patients in the treatment group achieve reduc-
tion in hematoma volume and neurological deficits as
compared to 50 % reduction in placebo control patients.
When the test power (1 − β) is 80 %, we will need to re-
cruit 52 patients in each treatment group based on a 2-
size data comparison to reach statistical significance.
When a 20 % drop-out rate is taken into the consider-
ation, the sample size is expanded to 126 patients. How-
ever, we propose to recruit 200 patients, with 50 %
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randomly assigned to the atorvastatin treatment group,
to meet the requirement of the CFDA for drug registra-
tion that the number of cases in treatment group shall
not be less than 100 in a phase II clinical trial.
Data analysis
A 2-tailed test will be performed and a p value of less
than or equal to 0.05 is considered to be statistically sig-
nificant. Statistical analysis will be performed by SAS 9.3
(SAS Institute Inc., Cary, NC, USA). The quantitative
parameters include group means, standard deviation,
median, minimum value and maximum value. A second-
ary descriptive analysis will summarize improvements of
neurological symptoms. For the secondary outcome
measures, neurological symptoms and clinical signs of
patients in each group are first to be described. Both
MGS-GCS and ADL-BI as measured at admission, 3 and
6 months are statistically compared using analysis of co-
variance (ANCOVA) with the treatment group as a fixed
effect and using MGS-GCS and ADL-BI baseline values
as covariates.
Data monitoring
Data monitoring and management will be performed by
Stemexcel Technology Company (Beijing Stemexcel
Technology Co., Ltd., Beijing, China).
The trial data are recorded in the electronic data man-
agement system (DAS for EDC). The CRF is designed
according to the protocol in order to collect trial data
and to define trial procedures. The form is finalized after
sponsors’ approval. CRF data from each participant will
be examined and verified by two investigators at a given
study site. The entered data will be systematically
checked by medically trained personnel. Errors will be
Table 2 Visit and assessment schedule















Concomitant medication1 √ √ √ √ √ √ √ √ √
Physical examination √ √ √ √ √ √ √ √
Surgery conversion √ √ √ √ √ √ √ √ √
Efficiency observation
Neurological symptoms2 √ √ √ √ √ √ √ √ √ √
Hematoma volume by CT2 √ √ √ √ √
MGS-GCS/ADL-BI2 √ √ √ √ √ √
GOS √ √ √ √
Safety assessment
Vital signs √ √ √ √ √ √ √ √ √ √
Blood routine/Coagulation √ √ √ √ √
Liver and renal function/Electrolyte/Lipids √ √ √ √ √
Urinalysis √ √ √
Electrocardiography √ √ √
Pregnancy test √
Adverse events √ √ √ √ √ √ √ √ √
Others
Drug dispensing √ √ √ √ √
Drug recovery3 √ √ √ √ √
ADL-BI Activities of Daily Life – the Barthel Index scale, CT computerized tomography, D day, GOS Glasgow Outcome Score, MGS-GCS Markwalder’s Grading Scale
and Glasgow Coma Scale
1Records of combination therapy are required until the end of the trial
2Surgical therapy is considered in the case of deterioration in neurological symptoms and/or signs, MGS-GCS grading and increase of hematoma immediately
imaging review then
3The remaining drugs need to be recovered
4At weeks 12 and 24, CT should be performed; other laboratory examinations will be selected when needed
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corrected by medically trained personnel and communi-
cated to the site investigators. The CRF will be inspected
by an assigned person at regular intervals throughout
the trial in order to verify the protocol compliance. The
entered data should be complete, consistent and
accurate.
SAEs
Severe adverse drug reaction/events (SAEs) refer to the
following conditions: death, life-threatening or perman-
ent or significant disability, permanent functional injury
to the organs, hospitalization for emergencies or pro-
longed hospitalization.
Once a SAE is confirmed in a patient, this patient will
be removed from the trial and a report should be filled
within 24 hours. A full report regarding SAEs should be
filled to the sponsor and SFDA. The ethics committee of
pharmaceutical affairs of ONET will conduct an investi-
gation to identify causes of SAEs and decide whether the
trial will be terminated. The severity of SAE, its relation-
ship with the trial medication, and treatments should be
recorded in the CRF. The above conditions are delivered
to the ethics committee of all participating hospitals.
Interim analysis
Interim analysis will not be conducted.
Auditing
Before the trial is ended, a serial quality control audit of
the database will be conducted.
Methodology
The ATOCH study is designed based on our previous
experience in treating CSDH with atorvastatin, showing
that 22 out of 23 patients achieved complete hematoma
elimination during the follow-up period after atorva-
statin treatment. We, therefore, expect a significant vol-
ume reduction in the hematomas of patients on
atorvastatin. However, since this is a conservative treat-
ment trial of a clinical condition that is traditionally
treated surgically, we limit our recruitment to patients
who have a small-medium volume of CSDH and whose
MGS-GCS is less than 3. To reduce adverse risks, espe-
cially patients on placebo, all patients will be closely
monitored for acute neurological deterioration. If neuro-
logical symptoms deteriorate during the trial, patients
will receive an emergency head CT scanning and neces-
sary surgery. Such patients will be removed from the
trial.
Except for rhabdomyolysis and impact on liver func-
tion, atorvastatin is considered to be generally very safe.
Thus, we do not plan to waive SAE for this trial proto-
col. If a patient develops any suspected related side ef-
fects, he or she will be immediately excluded. If
atorvastatin-related side effects are confirmed, treatment
will be terminated and affected patients will be followed
for 6 months.
Discussion
ATOCH is an atorvastatin-based clinical trial for CSDH.
To our knowledge, it is the first complete conservative
treatment trial for CSDH, undertaken in order to
Fig. 1 Flow chart to illustrate the design of the trial. ADL-BI, Activities of Daily Life – the Barthel Index scale, AEs adverse events, ECG
electrocardiography, GOS Glasgow Outcome Score, IWRS Interactive Web Response System, MGS-GCS Markwalder’s Grading Scale and
Glasgow Coma Scale
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exclude the influence of surgery as compared to previous
trials focusing on reducing the relapse of CSDH after
surgery. This trial is based on our previous data [14]
and on known effects of statins on modulating in-
flammation and enhancing angiogenesis [30, 31] as
reported for chronic obstructive pneumonic disease
(COPD) [32] and acute respiratory distress syndrome
(ARDS) [33]. We propose to test atorvastatin, but not
other statins, based on our published report on treat-
ing CSDH with atorvastatin.
We believe that this trial is necessary because options
for conservative treatment of CSDH are very limited
[34–36] . While cortisones were found effective in some
reports [1, 9–11, 37–39] by primarily blocking inflam-
mation and regulating angiogenesis, they often result in
a high incidence of complications at high dose. These
complications include digestive tract ulceration, increase
in plasma glucose, and deterioration in diabetes [40].
The long-term application of dexamethasone also in-
duces osteoporosis and decreases insulin sensitivity [41].
Perindopril is reported to reduce the relapse rate of
CSDH after surgery, but it has not been reported to treat
CSDH alone [13]. In contrast, we have shown that ator-
vastatin is an effective alternative to surgery for CSDH
because of its high efficacy and minimal side effects [14].
The most frequent side effect of atorvastatin is myop-
athy, which is believed to be dose-dependent and spon-
taneously resolves when atorvastatin is discontinued
[42]. The impairment of liver function by atorvastatin is
now believed to be very limited [43, 44]. Thus, atorva-
statin is expected to be safer than currently available
conservative therapies for CSDH. If atorvastatin is
proven to be effective through the ATOCH trial, we be-
lieve that it can become the therapeutic choice comple-
mentary to traditional surgical therapy with or without
medical intervention.
Trial status
The trial started in February 2014 and 96 patients have
now been enrolled.
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